Dept. Clinical Biochemistry, Jagiellonian University School of Medicine, Krakow, Poland.
Clin Nutr. 2009 Oct;28(5):510-5. doi: 10.1016/j.clnu.2009.04.016. Epub 2009 May 28.
BACKGROUND & AIMS: LDL phenotype B is associated with obesity, insulin resistance, hypertriglyceridemia and oxidative stress. The effect of plasma n-3/n-6 PUFA ratio on LDL phenotype transformation was investigated.
Patients with metabolic syndrome (n=99) received one of four isocaloric diets: (A) High-fat (38% energy) SFA-rich diet (HSFA); (B) High-fat (38% energy), MUFA-rich diet (HMUFA); (C), low-fat (LF) (28% energy), high-complex carbohydrate diet with 1.24g/d oleic sunflower oil (LFHCC) and (D): low-fat (28% energy), high-complex carbohydrate diet, with 1.24g/d LC n-3 PUFA (LFHCC n-3) for 12 weeks. Analysis of plasma lipid profile and LDL phenotype was done pre- and post-interventions.
Post-dietary change of LDL density was a main effect observed in all groups. LFHCC n-3 and HFMUFA diets resulted in favorable alteration of LDL phenotype from B to A and decreased LDL density. In contrast, increased LDL density was observed in HSFA and LFHCC groups. The plasma pre-n3/n6 PUFA, Apo E change and pre-Apo CIII/CII ratios explained in 65% the post-dietary change of LDL density in diet LFHCC n-3 consumers.
Study demonstrates efficacy of dietary n-3 PUFA to modify pro-atherogenic to less atherogenic LDL phenotype in patients with metabolic syndrome. Study identifier at ClinicalTrials.gov was NCT00429195.
LDL 表型 B 与肥胖、胰岛素抵抗、高三酰甘油血症和氧化应激有关。本研究旨在探讨血浆 n-3/n-6PUFA 比值对 LDL 表型转变的影响。
代谢综合征患者(n=99)接受以下四种等热量饮食中的一种:(A)高脂肪(38%能量)富含饱和脂肪酸饮食(HSFA);(B)高脂肪(38%能量)富含单不饱和脂肪酸饮食(HMUFA);(C)低脂肪(28%能量)、富含复杂碳水化合物的饮食,添加 1.24g/d 油酸葵花籽油(LFHCC);(D)低脂肪(28%能量)、富含复杂碳水化合物的饮食,添加 1.24g/dLCn-3PUFA(LFHCC n-3),共干预 12 周。干预前后对患者的血脂谱和 LDL 表型进行分析。
所有组均观察到 LDL 密度的饮食后变化是主要效应。LFHCC n-3 和 HFMUFA 饮食可使 LDL 表型从 B 转变为 A,并降低 LDL 密度。相比之下,HSFA 和 LFHCC 饮食会导致 LDL 密度增加。血浆 n-3/n-6PUFA 比值、载脂蛋白 E(Apo E)变化和前载脂蛋白 CIII/CII 比值的改变可以解释 LFHCC n-3 饮食者 LDL 密度饮食后变化的 65%。
本研究表明,饮食 n-3PUFA 可有效改善代谢综合征患者的致动脉粥样硬化性 LDL 表型为致动脉粥样硬化性较弱的 LDL 表型。本研究在 ClinicalTrials.gov 的注册号为 NCT00429195。